Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.
Decisions about future intensity of care made during a person-centered type 2 diabetes consultation depend on both disease- and patient-related factors, report researchers from the Netherlands.
Almost one in 10 people with type 2 diabetes who begin basal insulin therapy through the Medicare health program experience hypoglycemia within 6 months, US research suggests.
Second-line therapy choices for people with type 2 diabetes vary widely throughout the world and are influenced not only by clinical characteristics but also non-medical factors such as affordability and availability, results from the DISCOVER study show.
Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.
Older type 2 diabetes patients receiving basal insulin treatment who switch to glargine 300 units/mL experience greater or similar improvements in glycemic control compared with those switching to a first-generation basal insulin, with lower hypoglycemia risk, researchers report.
The quality of the evidence for the role of specific dietary factors in type 2 diabetes incidence is generally poor and requires better conducted research with more detailed assessments, suggests an umbrella review of meta-analyses.
Just over a third of people who undertook a period on a very-low-calorie diet in the DiRECT trial to tackle type 2 diabetes are in remission 24 months later, the investigators have reported.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.
Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.
